"The US Food and Drug Administration (FDA) has approved lusutrombopag (Mulpleta, Shionogi Inc) for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
In approving the thrombopoietin receptor agonist, the FDA reviewed data from two randomized, double-blind, placebo-controlled trials (L-PLUS 1 and L-PLUS 2). The trials involved 312 patients with chronic liver disease and severe thrombocytopenia who were to undergo an invasive procedure and whose platelet count was <50 x 109/L. Patients were randomly assigned to receive 3 mg of lusutrombopag or placebo once daily for up to 7 days."
- By Megan Brooks for Medscape.com